相关实验视频
Updated: May 5, 2026

09:29
Echocardiographic Assessment of the Right Heart in Mice
Published on: November 27, 2013
22.8K
汉克的心脏和动画为基础的教育为肺高血压
Michelle Cash1, Barbara Giambra2,3,4,5, Lara Stone6
1Heart Institute, Cincinnati Children's Hospital Medical Center Cincinnati Ohio USA.
Pulmonary circulation
|April 4, 2025
概括
针对儿科肺高血压 (PH) 的健康教育动画得到了好评,但不足. 患者和家人通过可联系的内容进行联系,强调需要个性化,持续的教育支持.
科学领域:
- 儿科健康 儿科健康
- 医学教育 医学教育
- 卫生识字 卫生识字
背景情况:
- 肺高血压 (PH) 是一种罕见,复杂的疾病,影响儿童和成人.
- 有效的健康教育对于患者和护理人员的决策至关重要.
- 了解患者和家庭对教育工具的看法至关重要.
研究的目的:
- 为了评估患者和家庭对"Hank the Heart"动画对健康素养的看法.
- 为未来的儿科肺高血压教育确定首选的学习方法.
主要方法:
- 一个定性研究,利用与患者和家庭护理人员的重点小组.
- 聚焦小组和采访成绩单的诱导性主题分析.
主要成果:
- "Hank the Heart"动画被认为是有帮助的,但对于教育需求来说并不全面.
- 患者和家人强烈认同动画人物及其对他们的经历的表现.
- 确定需要个性化,持续和量身定制的患者和家庭教育.
结论:
- 动画视频是儿童肺高血压的受欢迎教育方式.
- 患者和家庭的反为改善未来的教育动画开发提供了宝贵的见解.
- 定制,以患者为中心的教育对于解决复杂的健康和学习需求至关重要.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
911
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
911
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
694
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
694
Heart Failure II: Pathophysiology
2.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
2.1K
Heart Failure V: Medical Management
641
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
641
Heart Failure VI: Adjunct Therapies
635
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
635
Cardiomyopathy III: Hypertrophic Cardiomyopathy
810
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
810

